Financial Performance - The company's operating revenue for Q1 2022 was ¥2,184,192,085.97, representing a decrease of 8.99% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was ¥260,543,171.58, down by 2.37% year-on-year[5]. - The company's net profit for the current period is 214,844,440.33 CNY, a decrease of 13.06% compared to 247,198,278.37 CNY in the previous period[30]. - Operating profit for the current period is 268,017,651.01 CNY, down from 308,026,139.32 CNY, reflecting a decline of 12.99%[30]. - Total profit for the current period is 265,496,150.42 CNY, compared to 300,909,376.92 CNY in the previous period, indicating a decrease of 11.76%[30]. - The total comprehensive income attributable to the parent company's owners is 256,763,499.85 CNY, down from 263,083,185.84 CNY, a decrease of 2.43%[36]. - The basic earnings per share for the current period is 0.27 CNY, unchanged from the previous period[36]. Cash Flow - The net cash flow from operating activities was negative at ¥177,050,453.00, a significant decline of 535.29% compared to the previous year[5]. - The company's cash flow from operating activities shows a net outflow of -177,050,453.00 CNY, contrasting with a net inflow of 40,674,099.24 CNY in the previous period[36]. - Cash inflow from financing activities totaled ¥209,945,450, an increase of 47.8% compared to ¥142,089,400 in the previous period[38]. - Net cash flow from financing activities was ¥71,569,874.78, up from ¥32,772,757.33, representing a growth of 118.5%[38]. - The company reported a net decrease in cash and cash equivalents of ¥371,317,777.23, compared to a decrease of ¥108,554,448.09 in the previous period[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,570,948,928.69, showing a slight increase of 0.31% from the end of the previous year[7]. - Total liabilities decreased to CNY 3,176,492,996.76 from CNY 3,349,948,357.08, a reduction of 5.2%[24]. - The company's equity attributable to shareholders increased to CNY 9,042,539,568.35 from CNY 8,779,106,085.10, reflecting a growth of 3.0%[26]. - Short-term borrowings decreased to CNY 150,142,400.00 from CNY 176,123,955.84, a decline of 14.7%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,330[12]. - The largest shareholder, New Changxing Changxin Investment Development Co., Ltd., held 21.57% of the shares[13]. Operational Costs and Expenses - Total operating costs for Q1 2022 were CNY 1,884,014,155.71, down 10.7% from CNY 2,110,584,983.10 in Q1 2021[26]. - Research and development expenses in Q1 2022 amounted to CNY 172,997,815.13, a decrease of 32.3% compared to CNY 255,998,479.70 in Q1 2021[26]. - The company reported a decrease in interest income to 3,188,350.66 CNY from 3,597,606.80 CNY, a decline of 11.34%[30]. - Investment income for the current period significantly increased to 17,089,432.40 CNY from 3,905,500.84 CNY, marking a rise of 337.73%[30]. Other Financial Metrics - The weighted average return on net assets was 2.92%, a decrease of 0.5 percentage points compared to the previous year[5]. - The company did not conduct an audit for the quarterly report[5]. - The cash inflow from minority shareholders' investments was ¥12,089,400, which is included in the total cash inflow from financing activities[38]. - The cash inflow from operating activities totaled 2,068,968,525.42 CNY, down from 2,173,662,369.57 CNY, a decrease of 4.81%[36]. - The cash flow from operating activities was primarily impacted by complex domestic and international environments and rising raw material prices[9].
浙江医药(600216) - 2022 Q1 - 季度财报